Skip Navigation

This Article
Right arrow Print PDF (2464K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Pillaire, M.J.
Right arrow Articles by Gentil, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pillaire, M.J.
Right arrow Articles by Gentil, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1994, Vol. 22, No. 13 2519-2524
© 1994


RNA

Mutagenesis in monkey cells of a vector containing a single d(GPG) cis-diamminedichloroplatinum(ll) adduct placed on codon 13 of the human H-ras proto-oncogen

M.J. Pillaire, A. Margot1, G. Villani, A. Sarasin1, M. Defias and A. Gentil1,*

Laboratoire de Pharmacologie et de Toxicologie Fondamentales du CNRS 205 route de Narbonne, 31077 Toulouse cedex 1Laboratoire de Genetique Moléculaire, UPR 42, Institut de Recherches Scientifiques sur le Cancer BP 8, 94801 Villejuif, France

*To whom correspondence should be addressed.

Received April 12, 1994. Revised June 1, 1994. Accepted June 1, 1994.

Cisplatin (cis-{Pt(NH3)2Cl2}) is a widely used antitumor agent whose mutagenic activity raises the possibility of the induction of secondary cancer as a result of treatment. Mutation of the proto-oncogene H-ras is found in more than 30% of all human tumors, where it has been postulated to contribute to the initiation and progression of human cancers. Activating mutations in the H-ras gene are predominantly single-base substitutions, most frequently at codons 12,13 and 61. In the present work we have studied the mutational spectra induced by a single cis-{Pt(NH3)2d(GpG)} adduct, the most frequent DNA crosslink formed by cisplatin. We have constructed a 25-mer-Pt oligonucleotide singly modified at codon 13 (GGT) within the human H-ras DNA sequence and we have inserted it into a single-stranded SV40-based shuttle vector able to replicate in simian COS7 cells. After replication in the mammalian host, vectors were extracted, amplified in bacteria and DNA from 124 randomly chosen colonies was sequenced. The observed mutation frequency was 21%. Base substitutions were the most frequent modification. 92% of the mutagenic events occurred at one or both of the platinated guanines of codon 13. The single G—T transversion accounted for 65% of the total mutations scored. All single base substitutions were located at the G in the 3' position showing, for the first time, that the guanine at the 3' side of a cis-{Pt(NH3)2d(GpG)} adduct may be a preferential site for cisplatin induced mutations. The substitution G—T at this position of the codon 13 of the H-ras proto-oncogene is known to induce the oncogenic properties of the p21ras protein.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
J. A. Brown, S. A. Newmister, K. A. Fiala, and Z. Suo
Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase
Nucleic Acids Res., July 1, 2008; 36(12): 3867 - 3878.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Fourrier, P. Brooks, and J.-M. Malinge
Binding Discrimination of MutS to a Set of Lesions and Compound Lesions (Base Damage and Mismatch) Reveals Its Potential Role as a Cisplatin-damaged DNA Sensing Protein
J. Biol. Chem., May 30, 2003; 278(23): 21267 - 21275.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Vaisman and S. G. Chaney
The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase beta
J. Biol. Chem., April 21, 2000; 275(17): 13017 - 13025.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. Matton, J. Simonetti, and K. Williams
Inefficient in vivo repair of mismatches at an oncogenic hotspot correlated with lack of binding by mismatch repair proteins and with phase of the cell cycle
Carcinogenesis, August 1, 1999; 20(8): 1417 - 1424.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J.-S. Hoffmann, M.-J. Pillaire, C. Lesca, D. Burnouf, R. P. P. Fuchs, M. Defais, and G. Villani
Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates
PNAS, November 26, 1996; 93(24): 13766 - 13769.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-S. Hoffmann, M.-J. Pillaire, D. Garcia-Estefania, S. Lapalu, and G. Villani
In Vitro Bypass Replication of the Cisplatin-d(GpG) Lesion by Calf Thymus DNA Polymerase beta and Human Immunodeficiency Virus Type I Reverse Transcriptase Is Highly Mutagenic
J. Biol. Chem., June 28, 1996; 271(26): 15386 - 15392.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.